CRGE yields 9523.81% · JNJ yields 2.13%● Live data
📍 CRGE pulled ahead of the other in Year 1
Combined, CRGE + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CRGE + JNJ for your $10,000?
Charge Enterprises Inc. engages in building the electrification and telecommunications infrastructure for electric vehicle charging(EVC) and wireless network infrastructure, including 5G, tower, distributed antennae systems, small cell, and electrical infrastructure. The company operates through Telecommunications and Infrastructure segments. Its Telecommunications segment offers internet-protocol-based and time-division multiplexing access for transport of long-distance voice and data minutes; domestic switching and related peripheral equipment services, and carrier-grade routers and switches for internet and circuit-based services, as well as connection of voice calls and data services. The company's Infrastructure segment focuses on physical wireless networking elements including 4G and 5G, cell tower, small cell, and in-building applications and EVC solutions including design, engineering, vendor specification, construction, installation, and maintenance of electric vehicle chargers. This segment also offers network of personal charging power banks situated in bars, restaurants, transit hubs, and sporting arenas. The company was formerly known as TransWorld Holdings Inc and changed its name to Charge Enterprises, Inc. in January 2021.Charge Enterprises, Inc. was incorporated in 2003 and is based in New York, New York.
Full CRGE Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.